Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | RORA | P35398 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | RORB | Q92753 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600250 | 0.96 | CNR2 (0.76) | CNR2ALDH1A1HPGDPSEN1PSEN2 | |
| SCHEMBL27899823 | 0.95 | CNR2 (0.74) | CNR2ALDH1A1HPGDPSEN1PSEN2 | |
| SCHEMBL13415776 | 0.92 | ALDH1A1 (0.64) | CNR2ALDH1A1HPGDPSEN1PSEN2 | |
| SCHEMBL2212614 | 0.87 | CNR2 (0.56) | CNR2ALDH1A1HPGD | |
| SCHEMBL2215561 | 0.87 | CNR2 (0.76) | CNR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2215826 | 0.86 | CNR2 (0.56) | CNR2ALDH1A1HPGDFABP4FABP5 | |
| SCHEMBL2212394 | 0.86 | CNR2 (0.94) | CNR2ALDH1A1HPGDPSEN1PSEN2 | |
| SCHEMBL2216831 | 0.85 | CNR2 (0.80) | CNR2ALDH1A1HPGDPSEN1PSEN2 | |
| Hydrochloric Acid SCHEMBL27891826 | 0.85 | CNR2 (0.92) | CNR2ALDH1A1HPGDPSEN1PSEN2 | |
| SCHEMBL600437 | 0.82 | CNR2 (1.00) | CNR2ALDH1A1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | claimed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| CN-102952151-B | 3 double β carbolines alkaloid compounds, its preparation method and its pharmaceutical composition and purposes | 新疆华世丹药物研究有限责任公司 | 2017-07-28 | — | — | CN | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| CN-101429198-B | Banisterine derivant and uses thereof | XINJIANG HUASHIDAN MEDICAMENTS RES CO LTD | 2013-10-23 | — | — | CN | disclosed |
| CN-102952151-A | 3-position bis-beta-carboline alkali compound, and preparation method, pharmaceutical composition and application thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD | 2013-03-06 | — | — | CN | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | CNR2 156/4885ALDH1A1 324/4885HPGD 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.